Ariel Investments LLC boosted its position in shares of Vical (NASDAQ:VICL) by 9.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 637,913 shares of the biotechnology company’s stock after buying an additional 55,669 shares during the period. Ariel Investments LLC owned 3.43% of Vical worth $1,167,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of VICL. Acadian Asset Management LLC acquired a new position in Vical during the fourth quarter worth $140,000. Geode Capital Management LLC raised its stake in shares of Vical by 195.0% in the fourth quarter. Geode Capital Management LLC now owns 111,688 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 73,822 shares in the last quarter. Alambic Investment Management L.P. acquired a new stake in shares of Vical in the fourth quarter valued at $214,000. New York State Common Retirement Fund raised its stake in shares of Vical by 83.6% in the second quarter. New York State Common Retirement Fund now owns 130,706 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 59,504 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new position in Vical in the fourth quarter valued at $1,238,000. Institutional investors own 46.91% of the company’s stock.
In other Vical news, major shareholder Armistice Capital Master Fund bought 100,000 shares of Vical stock in a transaction that occurred on Monday, January 22nd. The shares were acquired at an average price of $1.43 per share, for a total transaction of $143,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 5.88% of the stock is owned by insiders.
Shares of Vical stock traded down $0.01 during trading on Monday, hitting $1.44. 175,634 shares of the company were exchanged, compared to its average volume of 223,312. Vical has a fifty-two week low of $1.32 and a fifty-two week high of $3.70. The company has a market capitalization of $31.63, a P/E ratio of -1.43 and a beta of 1.16.
Vical (NASDAQ:VICL) last released its earnings results on Thursday, March 15th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.10). Vical had a negative return on equity of 28.22% and a negative net margin of 93.78%. The firm had revenue of $3.95 million during the quarter, compared to analysts’ expectations of $4.60 million. equities research analysts expect that Vical will post -0.56 earnings per share for the current fiscal year.
Several equities analysts have issued reports on VICL shares. Zacks Investment Research raised Vical from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. HC Wainwright reissued a “buy” rating on shares of Vical in a report on Monday, January 22nd. Finally, ValuEngine raised Vical from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $5.25.
WARNING: This piece was posted by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://theenterpriseleader.com/2018/04/02/ariel-investments-llc-increases-holdings-in-vical-nasdaqvicl.html.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.